MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12325-025-03258-9

Медицинская библиотека · Advances in therapy · 2025

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.

Puig Luis, Sewerin Philipp, Schuster Christopher, Ng Khai Jing, Papadimitropoulos Manny, Gadagamma Sneha, Nuñez Mercedes, Lampropoulou Anastasia

СтатьяСистематический обзорПеревод в очереди

Аннотация

OBJECTIVE

To describe the results of a systematic literature review of real-world outcomes with ixekizumab in psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).

METHODS

Databases, conference proceedings, and additional sources were searched for real-world studies in ≥ 25 patients treated with ixekizumab for PsO, PsA, or axSpA. Data on clinical effectiveness, patient-reported outcomes, treatment patterns, safety, and economic burden were extracted.

RESULTS

A total of 118 publications were included, 96 in PsO, 16 in PsA, 5 in both PsO and PsA, and 1 in axSpA. Most focused on clinical effectiveness and treatment patterns. Ixekizumab was effective in real-world settings, and the anti-interleukin (IL)-17A biologics were more effective for skin clearance than comparator biologics. Anti-IL-17A biologics were effective for challenging body areas (nails, scalp, genitals, palmoplantar regions), and ixekizumab was associated with a higher chance of obtaining Dermatology Life Quality Index scores of 0/1 than secukinumab or other biologics. Ixekizumab was associated with generally high persistence/drug survival. No unexpected safety signals were identified.

CONCLUSION

Real-world ixekizumab use for PsO and PsA is effective and safe, with a positive impact on patient quality of life. More data are needed to draw conclusions for real-world ixekizumab use in axSpA.

Для цитирования: Puig Luis, Sewerin Philipp, Schuster Christopher, Ng Khai Jing, Papadimitropoulos Manny, Gadagamma Sneha, Nuñez Mercedes, Lampropoulou Anastasia. Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.. Advances in therapy. 2025. DOI: 10.1007/s12325-025-03258-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.